The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low…
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a…
GYNECOLOGICAL CANCER
Gut microbiome tied to therapy response in recurrent ovarian cancer
A person’s microbiome, or the collection of all microorganisms that live in the gut, can enhance the body’s antitumor response…
Most people with relapsed or refractory multiple myeloma (RRMM) given the cell therapy anitocabtagene autoleucel — known as anito-cel…
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier this year as a second-line treatment for people with multiple myeloma…
GYNECOLOGICAL CANCER
Vitamin D seen to prevent ovarian cancer’s onset in disease models
Vitamin D may help to prevent the development of ovarian cancers, according to new studies in mice and cell…
U.S. scientists have discovered that pediatric low-grade gliomas — a type of brain cancer that can occur in children —…
A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple…